Guardant Health Awards Stock Options and RSUs to New Employees Under Nasdaq Listing Rule 5635(c)(4)

Guardant Health has approved inducement grants to attract new employees, including restricted stock units for 239,565 shares and options for 23,542 shares. The stock options have an exercise price of $41.42, based on the closing price on August 1, 2025. The grants adhere to Nasdaq Listing Rule 5635(c)(4) and will vest annually or monthly over 24 months, contingent on ongoing employment.

Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, has announced the granting of restricted stock units (RSUs) and stock options to new non-executive employees. The grants, approved by the Compensation Committee of Guardant’s Board of Directors on July 22, 2025, are designed to attract and retain talent in line with Nasdaq Listing Rule 5635(c)(4).

The company granted RSUs representing 239,565 shares of its common stock to 189 new non-executive employees and two non-qualified stock option awards to purchase 23,542 shares of its common stock to two new non-executive employees. The stock options have an exercise price of $41.42 per share, which is equal to the closing price of Guardant’s common stock on The Nasdaq Global Select Market on August 1, 2025.

The RSUs and stock options will vest annually or monthly over 24 months, contingent on ongoing employment with Guardant Health. One-third of the shares underlying each RSU award will vest on an annual basis on the anniversary of the vesting commencement date, with the remaining two-thirds vesting on the subsequent anniversaries. For stock options, one-third of the shares will vest on the one-year anniversary of the vesting commencement date, with the remaining two-thirds vesting monthly over the next 24 months.

The Inducement Plan, under which these grants were made, is exclusively used for the grant of equity awards to individuals who were not previously employees of Guardant or following a bona fide period of non-employment, as an inducement material to such individuals’ entering into employment with Guardant. The grants are subject to the terms and conditions of the Inducement Plan and the respective award agreements covering the grants.

Guardant Health, founded in 2012, is transforming patient care by providing critical insights into what drives disease through its advanced blood and tissue tests, real-world data, and AI analytics. The company's tests help improve outcomes across all stages of care, including screening to find cancer early, monitoring for recurrence in early-stage cancer, and helping doctors select the best treatment for patients with advanced cancer.

References:
[1] https://www.nasdaq.com/press-release/guardant-health-announces-inducement-grants-under-nasdaq-listing-rule-5635c4-2025-08
[2] https://www.morningstar.com/news/business-wire/20250815731741/guardant-health-announces-inducement-grants-under-nasdaq-listing-rule-5635c4
[3] https://finance.yahoo.com/news/guardant-health-announces-inducement-grants-210500892.html